Drugs / TMZ
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06936046 Comparator | Jan 2025 → Jan 2027 expected | glioblastoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TMZ | “TMZ synchronous chemotherapy regimen: 75mg/m2 po qd.” NCT06936046 ↗ |
| Route | Oral | “TMZ synchronous chemotherapy regimen: 75mg/m2 po qd.” NCT06936046 ↗ |